Europe

Respiratory Health Priorities are Changing Across Europe – What Role Do Clinical Trial Sites Have to Play?

For decades, research into respiratory health has centered on conditions such as asthma and chronic obstructive pulmonary disease (COPD), predominantly because of their high prevalence. However, the incidence of respiratory diseases is increasing globally, with lesser-researched but equally debilitating conditions such as interstitial lung disease, pulmonary sarcoidosis, and pneumoconiosis affecting health statuses worldwide.  While clinical … Read more

The Start of Germany’s National Pharma Strategy: Implications for CROs and Clinical Trials

Over the past decade, Germany’s share of global clinical trial activities has dropped year on year. The country accounted for just 3.9% of trials in 2021, down from 7.2% in 2012. Late last year, the German Government published its National Pharma Strategy, which is designed to reverse this trend. Aiming to revitalize the country’s pharmaceutical … Read more

Nick Spittal Comments on Velocity’s Membership With Advarra’s Gene Therapy Ready Site Network

As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to conduct complex clinical research safely.” All Velocity sites are fully prepared … Read more

Dr. Watz Publishes 250th Paper, Leads Velocity’s Ahrensburg, Germany Site as the Top Enroller for a Global COPD Trial

Congratulations to Henrik Watz, MD, PhD, and our site in Ahrensburg (formerly Velocity Grosshansdorf), Germany, which is currently the top enroller for a global COPD trial! Dr. Watz has just published his 250th full paper, detailing results from the Phase 2 AIRLEAF trial. This study could pave the way for new treatment options in bronchiectasis, … Read more

Velocity appoints ICON exec Rachael Buck Ph.D. as Head of U.K.

Velocity Clinical Research, the leading multi-specialty clinical sites business, today announces the appointment of Rachael Buck Ph.D. as Country Head in the U.K. Rachael will lead the five sites Velocity currently owns and operates in the U.K. and will work with the rest of Velocity’s European executive team to expand the company’s footprint in the … Read more

Velocity Joins the IQVIA Connected Research Community in Europe

Velocity is proud to be a part of IQVIA’s Prime and Partner Site Programme. IQVIA have created a joint innovation group with representatives from their elite network of Prime and Super Partner sites across Europe, known as the “IQVIA Connected Research Community”. The purpose is to share ideas, lessons-learned, challenges, and innovations across our sites and … Read more

Velocity Expands to 17 Sites in Europe

Velocity Clinical Research, the leading multi-specialty clinical sites organization, today announces its further expansion in Europe, adding five sites in Poland after acquiring multi-site network KO-MED Centra Kliniczne and two in Germany, having acquired The Pulmonary Research Institute at the LungenClinic Grosshansdorf and KLB Gesundheitsforschung Lübeck. Velocity’s growth is accelerating across Europe, with 17 locations … Read more

Velocity Clinical Research Expands to Poland

Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has expanded into Poland, acquiring its first site, ClinMedica Research. Located in Skierniewice, which is halfway between Warsaw and Lodz, the site marks the first in a series of key acquisitions targeted by the company in Poland by year’s end.  In addition to being … Read more

Velocity Aggressively Expands MASH/MASLD Capabilities with Latest Site Acquisitions

Velocity Expands MASH/MASLD Capabilities With New Sites in Seattle, WA, and Waco, TX

Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease). According to the NASH education program, … Read more